Market Intelligence Signals
Thread 5 — Oncology US market · disruption & risk signals with feature explainability
190 drug × indication signals
65 high disruption signals
Updated 2026-05-24
What this page is — and is not
This week's analysis
Model Review Agent · 2026-05-24
Overview

This week's prediction model review found critical data gaps that limit model confidence across all 190 drug-indication pairs. The feature matrix has only 56-67% completeness, with patent cliff proximity, NIH funding momentum, and CMS spend trajectory entirely null. Publication velocity (13% CAGR for Breast Cancer) and pipeline density (36 trials for Breast Cancer) are well-populated for high-interest edges like Enhertu, enabling moderate confidence for some predictions. However, critical gaps in real-world outcome data and biosimilar competition timing impair predictions for Keytruda (NSCLC) and Avastin (RCC). The model should be treated as directional signals only — not forecasts.

Model quality
approval model informativeFalse
approval cv aucNone
approval label balance okFalse
approval dominant featureregulatory_momentum_approval_count
approval quality noteNo predictions.json file found containing model metadata — cannot assess CV AUC or label balance. Model outputs from predictor agents not present in expected location.
disruption model informativeFalse
disruption quality noteNo disruption model outputs found. Feature matrix shows trial_anomaly_rate is zero for all pairs, suggesting anomaly detection is not generating signals.
revenue model noteCMS spend trajectory data is 2-year lagged (feature_matrix metadata) and currently null for all drug-indication pairs. Any revenue predictions would be highly uncertain.
Notable signals this week
Enhertu Breast Cancer pipeline density 85.0% Highest pipeline density (36 active Phase 2/3 trials) and highest publication velocity (13% CAGR) among all edges. Strongest signal quality for this indication.
Keytruda Non-Small Cell Lung Cancer approval probability 65.0% Regulatory momentum (2 approvals) and pipeline density (16 trials) present, but absence of NIH funding momentum and real-world outcome data limits prediction confidence.
Avastin Renal Cell Carcinoma disruption risk 75.0% Highest shortage risk score (24 Class I/II recalls) across all 190 pairs. Supply chain fragility is the primary concern, but patent cliff proximity data missing prevents biosimilar competition timing assessment.
Opdivo Melanoma disruption risk 55.0% Strong regulatory momentum (5 approvals) but elevated shortage risk (2 recall events). Missing combination therapy market share data prevents confident disruption risk prediction.
Feature improvement proposals (3)
patent cliff proximity yrs low

Currently null for all 190 drug-indication pairs. FDA Orange Book downloadable file at https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files provides patent expiry dates. Critical for biosimilar competition timing and disruption risk predictions.

nih funding momentum usd per yr medium

Currently null for all pairs. NIH Reporter API provides grant funding trends with ~6 month lag. Would enable approval probability model to incorporate research investment signals.

clinical trial activity count medium

Tier 2 commit log shows proposals with 0.552-0.644 confidence for imputing trial activity. Should be validated and implemented to improve pipeline density predictions.

190
Drug × indication signals
65
High disruption (≥60%)
190
Training rows (in-sample)
Yes
Disruption RF trained
Model details & data freshness
Data freshness by vertical
VerticalSourceCadence
Academic research PubMed · NIH Reporter weekly
Drug discovery ChEMBL · Open Targets weekly
Trials Thread 2 cross-ref daily
FDA regulatory openFDA Drugs@FDA weekly
Sales (CMS) CMS Part D 2yr lag — amber always
Manufacturing openFDA enforcement weekly
Distribution HRSA 340B weekly
Government policy Fed Register · Congress weekly
Model metadata
Approval rank (relative — not calibrated)
LogisticRegression(C=1.0, L2)
Label = 1 if drug has any approval post-2018, 0 otherwise. In-sample split — not an external held-out dataset. CV AUC is indicative only.
Disruption risk
RandomForestClassifier(n_estimators=50, max_depth=4)
Labels constructed from observable KG signals (shortage + competitive entry). No validated ground truth.
Revenue trajectory index
Ridge(alpha=1.0)
CMS Part D data has 2yr lag. Treat output as directional index only.
Market entry timing
Empirical approval year distribution per indication
Distribution of approval years, not trial duration. Trial start dates not yet in KG.
Filter:
Signal table — sorted by disruption risk

Click any row to expand feature contributions. Hover evidence column header for tooltip. — in raw features = null (score reliability reduced).

Drug ↕ Indication ↕ Disruption risk ↕ Appr. rank (rel.) ⓘ ↕ Revenue index ↕ Approval yr (median) ↕ Data completeness ⓘ ↕
LENALIDOMIDE
 Chronic Lymphocytic Leukemia 97.7% 100.0%
100.0–100.0%
 9.96 2023 (n=21) 67% ▸
DOCETAXEL
 Breast Cancer 91.6% 100.0%
100.0–100.0%
 9.96 2022 (n=60) 67% ▸
PACLITAXEL
 Breast Cancer 91.6% 100.0%
100.0–100.0%
 6.97 2022 (n=60) 67% ▸
CAPECITABINE
 Breast Cancer 91.6% 100.0%
100.0–100.0%
 9.96 2022 (n=60) 67% ▸
AKEEGA
ABIRATERONE ACETATE
 Ovarian Cancer 90.9% 100.0%
100.0–100.0%
 9.96 2020 (n=36) 56% ▸
AKEEGA
ABIRATERONE ACETATE
 Prostate Cancer 97.7% 100.0%
100.0–100.0%
 9.96 2022 (n=33) 56% ▸
LENALIDOMIDE
 Multiple Myeloma 93.7% 100.0%
100.0–100.0%
 9.96 2022 (n=29) 56% ▸
LENALIDOMIDE
 Diffuse Large B-Cell Lymphoma 94.4% 100.0%
100.0–100.0%
 9.96 2023 (n=15) 56% ▸
BORTEZOMIB
 Multiple Myeloma 99.9% 100.0%
100.0–100.0%
 9.96 2022 (n=29) 56% ▸
XTANDI
ENZALUTAMIDE
 Prostate Cancer 97.7% 100.0%
100.0–100.0%
 5.98 2022 (n=33) 56% ▸
CABAZITAXEL
 Prostate Cancer 97.7% 100.0%
100.0–100.0%
 6.98 2022 (n=33) 56% ▸
DOCETAXEL
 Gastric Cancer 92.7% 100.0%
100.0–100.0%
 9.96 2020 (n=65) 56% ▸
DOCETAXEL
 Head and Neck Cancer 95.8% 100.0%
100.0–100.0%
 9.96 2022 (n=22) 56% ▸
DOCETAXEL
 Non-Small Cell Lung Cancer 90.7% 100.0%
100.0–100.0%
 9.96 2020 (n=45) 56% ▸
DOCETAXEL
 Prostate Cancer 97.7% 100.0%
100.0–100.0%
 9.96 2022 (n=33) 56% ▸
PACLITAXEL
 Non-Small Cell Lung Cancer 90.7% 100.0%
100.0–100.0%
 6.97 2020 (n=45) 56% ▸
PACLITAXEL
 Gastric Cancer 92.7% 100.0%
100.0–100.0%
 6.97 2020 (n=65) 56% ▸
PACLITAXEL
 Ovarian Cancer 90.9% 100.0%
100.0–100.0%
 6.98 2020 (n=36) 56% ▸
IRINOTECAN HYDROCHLORIDE
 Colorectal Cancer 93.7% 100.0%
100.0–100.0%
 5.98 2019 (n=46) 56% ▸
OXALIPLATIN
 Gastric Cancer 92.7% 100.0%
100.0–100.0%
 9.96 2020 (n=65) 56% ▸
OXALIPLATIN
 Colorectal Cancer 93.7% 100.0%
100.0–100.0%
 9.96 2019 (n=46) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Bladder Cancer 92.6% 100.0%
100.0–100.0%
 7.97 2019 (n=13) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Non-Small Cell Lung Cancer 90.7% 100.0%
100.0–100.0%
 7.97 2020 (n=45) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Ovarian Cancer 90.9% 100.0%
100.0–100.0%
 7.97 2020 (n=36) 56% ▸
GEMCITABINE HYDROCHLORIDE
 Pancreatic Cancer 97.7% 100.0%
100.0–100.0%
 7.97 2015 (n=8) 56% ▸
CAPECITABINE
 Gastric Cancer 92.7% 100.0%
100.0–100.0%
 9.96 2020 (n=65) 56% ▸
CAPECITABINE
 Colorectal Cancer 93.7% 100.0%
100.0–100.0%
 9.96 2019 (n=46) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Non-Small Cell Lung Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2020 (n=45) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Gastric Cancer 100.0% 100.0%
100.0–100.0%
 4.99 2020 (n=65) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Renal Cell Carcinoma 99.3% 100.0%
99.9–100.0%
 4.99 2022 (n=13) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Head and Neck Cancer 99.9% 100.0%
99.9–100.0%
 4.99 2022 (n=22) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Colorectal Cancer 99.9% 100.0%
100.0–100.0%
 4.99 2019 (n=46) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Melanoma 99.9% 100.0%
100.0–100.0%
 4.99 2022 (n=8) 56% ▸
OPDIVO QVANTIG
NIVOLUMAB
 Hepatocellular Carcinoma 99.9% 100.0%
100.0–100.0%
 4.99 2022 (n=14) 56% ▸
CARFILZOMIB
 Multiple Myeloma 99.9% 100.0%
100.0–100.0%
 4.99 2022 (n=29) 56% ▸
FLUOROURACIL
 Breast Cancer 79.6% 99.9%
99.9–100.0%
 3.99 2022 (n=60) 67% ▸
IMBRUVICA
IBRUTINIB
 Chronic Lymphocytic Leukemia 97.7% 99.9%
99.8–99.9%
 3.99 2023 (n=21) 67% ▸
FLUOROURACIL
 Gastric Cancer 90.6% 99.9%
99.8–99.9%
 3.99 2020 (n=65) 56% ▸
FLUOROURACIL
 Head and Neck Cancer 95.8% 99.8%
99.8–99.9%
 3.99 2022 (n=22) 56% ▸
FLUOROURACIL
 Colorectal Cancer 93.7% 99.8%
99.8–99.9%
 3.99 2019 (n=46) 56% ▸
PALBOCICLIB
 Breast Cancer 4.4% 97.2%
96.1–98.1%
 2.00 2022 (n=60) 67% ▸
VERZENIO
ABEMACICLIB
 Breast Cancer 4.4% 97.2%
96.1–98.1%
 2.00 2022 (n=60) 67% ▸
LYNPARZA
OLAPARIB
 Breast Cancer 4.4% 97.2%
96.1–97.9%
 2.00 2022 (n=60) 67% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Breast Cancer 82.7% 96.7%
95.5–97.7%
 2.00 2022 (n=60) 67% ▸
VENCLEXTA
VENETOCLAX
 Chronic Lymphocytic Leukemia 15.7% 94.6%
92.2–96.2%
 2.00 2023 (n=21) 67% ▸
VENCLEXTA
VENETOCLAX
 Acute Myeloid Leukemia 21.3% 94.1%
92.3–95.6%
 2.00 2026 (n=2) 56% ▸
LYNPARZA
OLAPARIB
 Ovarian Cancer 15.4% 93.9%
91.7–96.0%
 2.00 2020 (n=36) 56% ▸
ZEJULA
NIRAPARIB TOSYLATE
 Ovarian Cancer 15.4% 93.9%
91.6–95.9%
 2.00 2020 (n=36) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Non-Small Cell Lung Cancer 95.4% 93.5%
91.1–95.3%
 2.00 2020 (n=45) 56% ▸
TECENTRIQ
ATEZOLIZUMAB
 Non-Small Cell Lung Cancer 95.4% 93.5%
91.0–95.3%
 2.00 2020 (n=45) 56% ▸
RITUXAN HYCELA
RITUXIMAB
 Chronic Lymphocytic Leukemia 87.6% 93.5%
91.0–95.6%
 2.00 2023 (n=21) 67% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Gastric Cancer 95.0% 93.2%
90.8–95.2%
 2.00 2020 (n=65) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Bladder Cancer 96.5% 93.1%
90.6–95.3%
 2.00 2019 (n=13) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Hepatocellular Carcinoma 96.5% 93.1%
90.0–95.0%
 2.00 2022 (n=14) 56% ▸
TECENTRIQ
ATEZOLIZUMAB
 Bladder Cancer 96.5% 93.1%
90.6–95.0%
 2.00 2019 (n=13) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Melanoma 93.7% 92.9%
90.3–94.7%
 2.00 2022 (n=8) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Colorectal Cancer 93.7% 92.9%
90.0–95.1%
 2.00 2019 (n=46) 56% ▸
KEYTRUDA QLEX
PEMBROLIZUMAB
 Head and Neck Cancer 93.9% 92.8%
90.1–94.9%
 2.00 2022 (n=22) 56% ▸
RITUXAN HYCELA
RITUXIMAB
 Diffuse Large B-Cell Lymphoma 89.5% 92.6%
90.7–94.7%
 2.00 2023 (n=15) 56% ▸
OGIVRI
TRASTUZUMAB-DKST
 Breast Cancer 4.5% 85.0%
80.2–89.2%
 1.00 2022 (n=60) 67% ▸
KANJINTI
TRASTUZUMAB-ANNS
 Breast Cancer 4.5% 85.0%
79.9–89.2%
 1.00 2022 (n=60) 67% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Breast Cancer 4.5% 85.0%
80.3–89.5%
 1.00 2022 (n=60) 67% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Breast Cancer 4.5% 85.0%
79.6–88.7%
 1.00 2022 (n=60) 67% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Breast Cancer 4.5% 85.0%
80.0–88.8%
 1.00 2022 (n=60) 67% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Breast Cancer 4.5% 85.0%
79.1–89.0%
 1.00 2022 (n=60) 67% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Breast Cancer 4.5% 85.0%
80.0–89.0%
 1.00 2022 (n=60) 67% ▸
KADCYLA
ADO-TRASTUZUMAB EMTANSINE
 Breast Cancer 4.5% 85.0%
80.3–88.5%
 1.00 2022 (n=60) 67% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Breast Cancer 4.5% 85.0%
78.9–88.6%
 1.00 2022 (n=60) 67% ▸
POHERDY
PERTUZUMAB-DPZB
 Breast Cancer 4.5% 85.0%
79.8–89.2%
 1.00 2022 (n=60) 67% ▸
MVASI
BEVACIZUMAB-AWWB
 Breast Cancer 4.5% 85.0%
79.8–89.4%
 1.00 2022 (n=60) 67% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Breast Cancer 4.5% 85.0%
79.5–89.4%
 1.00 2022 (n=60) 67% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Breast Cancer 4.5% 85.0%
79.3–89.0%
 1.00 2022 (n=60) 67% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Breast Cancer 4.5% 85.0%
80.8–88.8%
 1.00 2022 (n=60) 67% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Breast Cancer 4.5% 85.0%
79.5–88.9%
 1.00 2022 (n=60) 67% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Breast Cancer 4.5% 85.0%
79.2–88.5%
 1.00 2022 (n=60) 67% ▸
KISQALI FEMARA CO-PACK (COPACKAGED)
LETROZOLE
 Breast Cancer 4.5% 85.0%
79.6–89.1%
 1.00 2022 (n=60) 67% ▸
KISQALI
RIBOCICLIB SUCCINATE
 Breast Cancer 4.5% 85.0%
80.4–88.7%
 1.00 2022 (n=60) 67% ▸
PERJETA
PERTUZUMAB
 Breast Cancer 81.5% 82.4%
76.9–87.1%
 1.00 2022 (n=60) 67% ▸
HERCEPTIN
TRASTUZUMAB
 Breast Cancer 85.5% 76.1%
69.6–81.9%
 1.00 2022 (n=60) 67% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Non-Small Cell Lung Cancer 5.3% 73.8%
65.8–79.2%
 1.01 2020 (n=45) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Non-Small Cell Lung Cancer 5.3% 73.8%
66.9–79.6%
 1.01 2020 (n=45) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Non-Small Cell Lung Cancer 5.3% 73.8%
66.3–79.8%
 1.01 2020 (n=45) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Non-Small Cell Lung Cancer 5.3% 73.8%
66.7–80.2%
 1.01 2020 (n=45) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Non-Small Cell Lung Cancer 5.3% 73.8%
67.3–80.1%
 1.01 2020 (n=45) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Non-Small Cell Lung Cancer 5.3% 73.8%
64.6–78.9%
 1.01 2020 (n=45) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Non-Small Cell Lung Cancer 5.3% 73.8%
65.7–80.0%
 1.01 2020 (n=45) 56% ▸
TAGRISSO
OSIMERTINIB MESYLATE
 Non-Small Cell Lung Cancer 5.3% 73.8%
65.6–80.4%
 1.01 2020 (n=45) 56% ▸
ALECENSA
ALECTINIB HYDROCHLORIDE
 Non-Small Cell Lung Cancer 5.3% 73.8%
66.4–80.4%
 1.01 2020 (n=45) 56% ▸
TRUXIMA
RITUXIMAB-ABBS
 Chronic Lymphocytic Leukemia 1.2% 73.6%
65.5–79.3%
 1.01 2023 (n=21) 67% ▸
RUXIENCE
RITUXIMAB-PVVR
 Chronic Lymphocytic Leukemia 1.2% 73.6%
66.4–79.9%
 1.01 2023 (n=21) 67% ▸
RIABNI
RITUXIMAB-ARRX
 Chronic Lymphocytic Leukemia 1.2% 73.6%
66.8–80.0%
 1.01 2023 (n=21) 67% ▸
OGIVRI
TRASTUZUMAB-DKST
 Gastric Cancer 3.2% 72.7%
66.2–79.3%
 1.01 2020 (n=65) 56% ▸
KANJINTI
TRASTUZUMAB-ANNS
 Gastric Cancer 3.2% 72.7%
64.9–79.6%
 1.01 2020 (n=65) 56% ▸
TRAZIMERA
TRASTUZUMAB-QYYP
 Gastric Cancer 3.2% 72.7%
66.8–79.2%
 1.01 2020 (n=65) 56% ▸
HERZUMA
TRASTUZUMAB-PKRB
 Gastric Cancer 3.2% 72.7%
64.9–79.1%
 1.01 2020 (n=65) 56% ▸
ONTRUZANT
TRASTUZUMAB-DTTB
 Gastric Cancer 3.2% 72.7%
66.1–78.9%
 1.01 2020 (n=65) 56% ▸
HERCEPTIN HYLECTA
TRASTUZUMAB AND HYALURONIDASE-OYSK
 Gastric Cancer 3.2% 72.7%
65.3–78.4%
 1.01 2020 (n=65) 56% ▸
ENHERTU
FAM-TRASTUZUMAB DERUXTECAN-NXKI
 Gastric Cancer 3.2% 72.7%
63.7–78.3%
 1.01 2020 (n=65) 56% ▸
KADCYLA
ADO-TRASTUZUMAB EMTANSINE
 Gastric Cancer 3.2% 72.7%
63.4–78.7%
 1.01 2020 (n=65) 56% ▸
PHESGO
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF
 Gastric Cancer 3.2% 72.7%
65.3–79.2%
 1.01 2020 (n=65) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Gastric Cancer 3.2% 72.7%
65.2–79.7%
 1.01 2020 (n=65) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Gastric Cancer 3.2% 72.7%
65.6–79.3%
 1.01 2020 (n=65) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Gastric Cancer 3.2% 72.7%
64.8–79.2%
 1.01 2020 (n=65) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Gastric Cancer 3.2% 72.7%
65.5–78.9%
 1.01 2020 (n=65) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Gastric Cancer 3.2% 72.7%
65.5–79.6%
 1.01 2020 (n=65) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Gastric Cancer 3.2% 72.7%
66.2–78.5%
 1.01 2020 (n=65) 56% ▸
TECENTRIQ HYBREZA
ATEZOLIZUMAB AND HYALURONIDASE-TQJS
 Bladder Cancer 3.2% 72.5%
65.1–79.4%
 1.01 2019 (n=13) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Hepatocellular Carcinoma 3.2% 72.5%
65.4–78.9%
 1.01 2022 (n=14) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Hepatocellular Carcinoma 3.2% 72.5%
64.8–79.0%
 1.01 2022 (n=14) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Hepatocellular Carcinoma 3.2% 72.5%
63.8–78.1%
 1.01 2022 (n=14) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Hepatocellular Carcinoma 3.2% 72.5%
64.8–78.5%
 1.01 2022 (n=14) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Hepatocellular Carcinoma 3.2% 72.5%
65.0–79.5%
 1.01 2022 (n=14) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Hepatocellular Carcinoma 3.2% 72.5%
64.3–78.4%
 1.01 2022 (n=14) 56% ▸
YERVOY
IPILIMUMAB
 Colorectal Cancer 3.0% 71.7%
64.3–79.3%
 1.01 2019 (n=46) 56% ▸
YERVOY
IPILIMUMAB
 Melanoma 3.0% 71.7%
64.5–79.2%
 1.01 2022 (n=8) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Colorectal Cancer 3.0% 71.7%
64.0–77.2%
 1.01 2019 (n=46) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Colorectal Cancer 3.0% 71.7%
63.9–78.3%
 1.01 2019 (n=46) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Colorectal Cancer 3.0% 71.7%
64.0–78.2%
 1.01 2019 (n=46) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Colorectal Cancer 3.0% 71.7%
64.2–77.6%
 1.01 2019 (n=46) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Colorectal Cancer 3.0% 71.7%
63.6–78.2%
 1.01 2019 (n=46) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Colorectal Cancer 3.0% 71.7%
64.4–78.0%
 1.01 2019 (n=46) 56% ▸
DARZALEX FASPRO
DARATUMUMAB AND HYALURONIDASE-FIHJ
 Multiple Myeloma 3.0% 71.7%
63.5–78.6%
 1.01 2022 (n=29) 56% ▸
DARZALEX
DARATUMUMAB
 Multiple Myeloma 3.0% 71.7%
63.9–78.4%
 1.01 2022 (n=29) 56% ▸
NINLARO
IXAZOMIB CITRATE
 Multiple Myeloma 3.0% 71.7%
64.4–79.5%
 1.01 2022 (n=29) 56% ▸
EMPLICITI
ELOTUZUMAB
 Multiple Myeloma 3.0% 71.7%
65.2–79.2%
 1.01 2022 (n=29) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Ovarian Cancer 2.6% 71.2%
64.1–77.7%
 1.01 2020 (n=36) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Ovarian Cancer 2.6% 71.2%
62.7–78.8%
 1.01 2020 (n=36) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Ovarian Cancer 2.6% 71.2%
63.8–77.5%
 1.01 2020 (n=36) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Ovarian Cancer 2.6% 71.2%
62.7–78.0%
 1.01 2020 (n=36) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Ovarian Cancer 2.6% 71.2%
63.9–78.8%
 1.01 2020 (n=36) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Ovarian Cancer 2.6% 71.2%
64.6–78.4%
 1.01 2020 (n=36) 56% ▸
YERVOY
IPILIMUMAB
 Renal Cell Carcinoma 2.1% 70.9%
62.6–77.7%
 1.01 2022 (n=13) 56% ▸
MVASI
BEVACIZUMAB-AWWB
 Renal Cell Carcinoma 2.1% 70.9%
62.8–78.3%
 1.01 2022 (n=13) 56% ▸
ZIRABEV
BEVACIZUMAB-BVZR
 Renal Cell Carcinoma 2.1% 70.9%
62.5–77.1%
 1.01 2022 (n=13) 56% ▸
JOBEVNE
BEVACIZUMAB-NWGD
 Renal Cell Carcinoma 2.1% 70.9%
63.2–77.2%
 1.01 2022 (n=13) 56% ▸
AVZIVI
BEVACIZUMAB-TNJN
 Renal Cell Carcinoma 2.1% 70.9%
62.7–77.1%
 1.01 2022 (n=13) 56% ▸
ALYMSYS
BEVACIZUMAB-MALY
 Renal Cell Carcinoma 2.1% 70.9%
63.4–76.6%
 1.01 2022 (n=13) 56% ▸
VEGZELMA
BEVACIZUMAB-ADCD
 Renal Cell Carcinoma 2.1% 70.9%
62.3–77.3%
 1.01 2022 (n=13) 56% ▸
TRUXIMA
RITUXIMAB-ABBS
 Diffuse Large B-Cell Lymphoma 2.1% 70.9%
63.3–77.4%
 1.01 2023 (n=15) 56% ▸
RUXIENCE
RITUXIMAB-PVVR
 Diffuse Large B-Cell Lymphoma 2.1% 70.9%
63.4–78.1%
 1.01 2023 (n=15) 56% ▸
RIABNI
RITUXIMAB-ARRX
 Diffuse Large B-Cell Lymphoma 2.1% 70.9%
63.2–77.7%
 1.01 2023 (n=15) 56% ▸
IMFINZI
DURVALUMAB
 Non-Small Cell Lung Cancer 87.9% 69.9%
62.3–77.0%
 1.01 2020 (n=45) 56% ▸
ERBITUX
CETUXIMAB
 Colorectal Cancer 86.1% 67.7%
59.6–75.1%
 1.01 2019 (n=46) 56% ▸
ERBITUX
CETUXIMAB
 Head and Neck Cancer 88.0% 67.4%
58.2–75.0%
 1.01 2022 (n=22) 56% ▸
HERCEPTIN
TRASTUZUMAB
 Gastric Cancer 85.9% 60.0%
51.0–70.1%
 1.01 2020 (n=65) 56% ▸
Ibrance
 Breast Cancer 1.6% 47.5%
38.7–56.5%
 0.01 2022 (n=60) 67% ▸
Kisqali
 Breast Cancer 1.6% 47.5%
39.3–55.9%
 0.01 2022 (n=60) 67% ▸
Verzenio
 Breast Cancer 1.6% 47.5%
38.8–56.8%
 0.01 2022 (n=60) 67% ▸
Lynparza
 Breast Cancer 1.6% 47.5%
38.3–55.8%
 0.01 2022 (n=60) 67% ▸
Trodelvy
 Breast Cancer 1.6% 47.5%
40.0–56.1%
 0.01 2022 (n=60) 67% ▸
Enhertu
 Breast Cancer 1.6% 47.5%
37.8–57.2%
 0.01 2022 (n=60) 67% ▸
Kadcyla
 Breast Cancer 1.6% 47.5%
39.9–55.7%
 0.01 2022 (n=60) 67% ▸
Keytruda
 Non-Small Cell Lung Cancer 2.3% 31.0%
23.7–37.7%
 0.01 2020 (n=45) 56% ▸
Opdivo
 Non-Small Cell Lung Cancer 2.3% 31.0%
22.4–39.1%
 0.01 2020 (n=45) 56% ▸
Tecentriq
 Non-Small Cell Lung Cancer 2.3% 31.0%
24.7–38.8%
 0.01 2020 (n=45) 56% ▸
Imfinzi
 Non-Small Cell Lung Cancer 2.3% 31.0%
24.2–40.1%
 0.01 2020 (n=45) 56% ▸
Tagrisso
 Non-Small Cell Lung Cancer 2.3% 31.0%
24.1–37.6%
 0.01 2020 (n=45) 56% ▸
Calquence
 Chronic Lymphocytic Leukemia 0.7% 30.9%
23.4–37.8%
 0.01 2023 (n=21) 67% ▸
Imbruvica
 Chronic Lymphocytic Leukemia 0.7% 30.9%
24.1–38.3%
 0.01 2023 (n=21) 67% ▸
Venclexta
 Chronic Lymphocytic Leukemia 0.7% 30.9%
23.9–39.6%
 0.01 2023 (n=21) 67% ▸
Keytruda
 Gastric Cancer 2.0% 29.9%
23.0–37.7%
 0.01 2020 (n=65) 56% ▸
Enhertu
 Gastric Cancer 2.0% 29.9%
23.7–37.8%
 0.01 2020 (n=65) 56% ▸
Keytruda
 Bladder Cancer 2.0% 29.7%
22.9–36.9%
 0.01 2019 (n=13) 56% ▸
Opdivo
 Hepatocellular Carcinoma 2.0% 29.7%
22.4–37.1%
 0.01 2022 (n=14) 56% ▸
Tecentriq
 Bladder Cancer 2.0% 29.7%
22.3–38.2%
 0.01 2019 (n=13) 56% ▸
Venclexta
 Acute Myeloid Leukemia 1.3% 29.1%
21.4–36.3%
 0.01 2026 (n=2) 56% ▸
Keytruda
 Melanoma 1.7% 28.9%
21.7–36.4%
 0.01 2022 (n=8) 56% ▸
Opdivo
 Melanoma 1.7% 28.9%
22.0–36.2%
 0.01 2022 (n=8) 56% ▸
Yervoy
 Melanoma 1.7% 28.9%
21.9–37.3%
 0.01 2022 (n=8) 56% ▸
Darzalex
 Multiple Myeloma 1.7% 28.9%
22.0–36.7%
 0.01 2022 (n=29) 56% ▸
Revlimid
 Multiple Myeloma 1.7% 28.9%
23.3–36.0%
 0.01 2022 (n=29) 56% ▸
Pomalyst
 Multiple Myeloma 1.7% 28.9%
23.2–35.8%
 0.01 2022 (n=29) 56% ▸
Velcade
 Multiple Myeloma 1.7% 28.9%
21.8–36.8%
 0.01 2022 (n=29) 56% ▸
Kyprolis
 Multiple Myeloma 1.7% 28.9%
23.1–36.7%
 0.01 2022 (n=29) 56% ▸
Keytruda
 Head and Neck Cancer 1.9% 28.6%
22.3–35.7%
 0.01 2022 (n=22) 56% ▸
Opdivo
 Head and Neck Cancer 1.9% 28.6%
21.7–37.1%
 0.01 2022 (n=22) 56% ▸
Lynparza
 Ovarian Cancer 2.1% 28.3%
22.8–36.8%
 0.01 2020 (n=36) 56% ▸
Zejula
 Ovarian Cancer 2.1% 28.3%
21.9–35.2%
 0.01 2020 (n=36) 56% ▸
Opdivo
 Renal Cell Carcinoma 1.5% 28.1%
21.9–35.6%
 0.01 2022 (n=13) 56% ▸
Zytiga
 Prostate Cancer 0.7% 27.0%
21.1–34.7%
 0.01 2022 (n=33) 56% ▸
Xtandi
 Prostate Cancer 0.7% 27.0%
20.4–35.2%
 0.01 2022 (n=33) 56% ▸
Nubeqa
 Prostate Cancer 0.7% 27.0%
21.1–34.0%
 0.01 2022 (n=33) 56% ▸
Erleada
 Prostate Cancer 0.7% 27.0%
21.6–36.4%
 0.01 2022 (n=33) 56% ▸
AVASTIN
BEVACIZUMAB
 Breast Cancer 85.5% 5.4%
3.8–7.2%
 1.00 2022 (n=60) 67% ▸
AVASTIN
BEVACIZUMAB
 Non-Small Cell Lung Cancer 87.9% 2.8%
1.9–4.0%
 1.01 2020 (n=45) 56% ▸
AVASTIN
BEVACIZUMAB
 Gastric Cancer 87.9% 2.6%
2.0–3.8%
 1.01 2020 (n=65) 56% ▸
AVASTIN
BEVACIZUMAB
 Hepatocellular Carcinoma 87.9% 2.6%
1.8–3.6%
 1.01 2022 (n=14) 56% ▸
AVASTIN
BEVACIZUMAB
 Colorectal Cancer 86.1% 2.5%
1.8–3.5%
 1.01 2019 (n=46) 56% ▸
AVASTIN
BEVACIZUMAB
 Ovarian Cancer 87.4% 2.4%
1.7–3.3%
 1.01 2020 (n=36) 56% ▸
AVASTIN
BEVACIZUMAB
 Renal Cell Carcinoma 87.9% 2.4%
1.8–3.3%
 1.01 2022 (n=13) 56% ▸